RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The purpose of this study was to test the hypothesis that the immunohistochemical expression of ERCC1 and RASSF1A would predict both response to and survival after docetaxel and cisplatin combination chemotherapy in inoperable or recurrent head and neck squamous cell carcinoma. Patients and Methods: A total of 54 patients were treated with frontline systemic chemotherapy composed of docetaxel (60 mg/m2) and cisplatin (65 mg/m2), every 3 weeks for up to 6 cycles. The expression levels of ERCC1 and RASSF1A were evaluated in the available 36 prechemotherapy samples. Results: The overall objective response rate was 35% (complete remission 12% and partial remission 23%). The median progression-free survival and overall survival (OS) times were 5.0 months (95% confidence interval (CI), 3.7-6.4 months) and 24.2 months (95% CI, 3.5-45.0 months), respectively. The status of low ERCC1 and high RASSF1A expression was an independent favorable prognostic factor for OS in multivariate analysis (p = 0.043; hazard ratio, 7.224; 95% CI, 1.060-49.217). Toxicities were comparable with those of previously reported trials. Conclusions: Less intensive doses of cisplatin and docetaxel are active but not effective in reducing toxicity. Also, both ERCC1 and RASSF1A might be useful prognostic markers in this regimen.

Original languageEnglish
Pages (from-to)673-682
Number of pages10
JournalOnkologie
Volume35
Issue number11
DOIs
Publication statusPublished - 2012 Nov 1

Fingerprint

docetaxel
Cisplatin
Confidence Intervals
Survival
Combination Drug Therapy
Disease-Free Survival
Multivariate Analysis
Drug Therapy
Carcinoma, squamous cell of head and neck

Keywords

  • Cisplatin
  • Docetaxel
  • ERCC1
  • RASSF1A
  • Squamous cell carcinoma of the head and neck

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

@article{062fa2245f3541fab915d153224308b7,
title = "RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin",
abstract = "Background: The purpose of this study was to test the hypothesis that the immunohistochemical expression of ERCC1 and RASSF1A would predict both response to and survival after docetaxel and cisplatin combination chemotherapy in inoperable or recurrent head and neck squamous cell carcinoma. Patients and Methods: A total of 54 patients were treated with frontline systemic chemotherapy composed of docetaxel (60 mg/m2) and cisplatin (65 mg/m2), every 3 weeks for up to 6 cycles. The expression levels of ERCC1 and RASSF1A were evaluated in the available 36 prechemotherapy samples. Results: The overall objective response rate was 35{\%} (complete remission 12{\%} and partial remission 23{\%}). The median progression-free survival and overall survival (OS) times were 5.0 months (95{\%} confidence interval (CI), 3.7-6.4 months) and 24.2 months (95{\%} CI, 3.5-45.0 months), respectively. The status of low ERCC1 and high RASSF1A expression was an independent favorable prognostic factor for OS in multivariate analysis (p = 0.043; hazard ratio, 7.224; 95{\%} CI, 1.060-49.217). Toxicities were comparable with those of previously reported trials. Conclusions: Less intensive doses of cisplatin and docetaxel are active but not effective in reducing toxicity. Also, both ERCC1 and RASSF1A might be useful prognostic markers in this regimen.",
keywords = "Cisplatin, Docetaxel, ERCC1, RASSF1A, Squamous cell carcinoma of the head and neck",
author = "Yong Park and Kim, {Dae Sik} and Park, {Kyong Hwa} and Seung-Kuk Baek and Kwon, {Soon Young} and Shin, {Sang Won} and Kwang-Yoon Jung and Kim, {Chul Yong} and Kim, {Yeol H.} and Nam-Joon Lee and Kim, {Jun Suk} and Kim, {In S.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1159/000343636",
language = "English",
volume = "35",
pages = "673--682",
journal = "Oncology Research and Treatment",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "11",

}

TY - JOUR

T1 - RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin

AU - Park, Yong

AU - Kim, Dae Sik

AU - Park, Kyong Hwa

AU - Baek, Seung-Kuk

AU - Kwon, Soon Young

AU - Shin, Sang Won

AU - Jung, Kwang-Yoon

AU - Kim, Chul Yong

AU - Kim, Yeol H.

AU - Lee, Nam-Joon

AU - Kim, Jun Suk

AU - Kim, In S.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Background: The purpose of this study was to test the hypothesis that the immunohistochemical expression of ERCC1 and RASSF1A would predict both response to and survival after docetaxel and cisplatin combination chemotherapy in inoperable or recurrent head and neck squamous cell carcinoma. Patients and Methods: A total of 54 patients were treated with frontline systemic chemotherapy composed of docetaxel (60 mg/m2) and cisplatin (65 mg/m2), every 3 weeks for up to 6 cycles. The expression levels of ERCC1 and RASSF1A were evaluated in the available 36 prechemotherapy samples. Results: The overall objective response rate was 35% (complete remission 12% and partial remission 23%). The median progression-free survival and overall survival (OS) times were 5.0 months (95% confidence interval (CI), 3.7-6.4 months) and 24.2 months (95% CI, 3.5-45.0 months), respectively. The status of low ERCC1 and high RASSF1A expression was an independent favorable prognostic factor for OS in multivariate analysis (p = 0.043; hazard ratio, 7.224; 95% CI, 1.060-49.217). Toxicities were comparable with those of previously reported trials. Conclusions: Less intensive doses of cisplatin and docetaxel are active but not effective in reducing toxicity. Also, both ERCC1 and RASSF1A might be useful prognostic markers in this regimen.

AB - Background: The purpose of this study was to test the hypothesis that the immunohistochemical expression of ERCC1 and RASSF1A would predict both response to and survival after docetaxel and cisplatin combination chemotherapy in inoperable or recurrent head and neck squamous cell carcinoma. Patients and Methods: A total of 54 patients were treated with frontline systemic chemotherapy composed of docetaxel (60 mg/m2) and cisplatin (65 mg/m2), every 3 weeks for up to 6 cycles. The expression levels of ERCC1 and RASSF1A were evaluated in the available 36 prechemotherapy samples. Results: The overall objective response rate was 35% (complete remission 12% and partial remission 23%). The median progression-free survival and overall survival (OS) times were 5.0 months (95% confidence interval (CI), 3.7-6.4 months) and 24.2 months (95% CI, 3.5-45.0 months), respectively. The status of low ERCC1 and high RASSF1A expression was an independent favorable prognostic factor for OS in multivariate analysis (p = 0.043; hazard ratio, 7.224; 95% CI, 1.060-49.217). Toxicities were comparable with those of previously reported trials. Conclusions: Less intensive doses of cisplatin and docetaxel are active but not effective in reducing toxicity. Also, both ERCC1 and RASSF1A might be useful prognostic markers in this regimen.

KW - Cisplatin

KW - Docetaxel

KW - ERCC1

KW - RASSF1A

KW - Squamous cell carcinoma of the head and neck

UR - http://www.scopus.com/inward/record.url?scp=84870051832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870051832&partnerID=8YFLogxK

U2 - 10.1159/000343636

DO - 10.1159/000343636

M3 - Article

C2 - 23147544

AN - SCOPUS:84870051832

VL - 35

SP - 673

EP - 682

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - 11

ER -